HYLOMORPH successfully raises 5.2M CHF during Series-B round
03-12-2021 – The Wyss Zurich alumni project HYLOMORPH, a rapidly growing clinical-stage medtech startup with a history of national and international recognition, completed a CHF 5.2 million Series-B financing round. At the same time, the company attracted CHF 0.9 million in new non-dilutive funding.
This financing round aims at safely bringing the company to FDA and CE mark approval of its product portfolio, beginning with the blockbuster Hylomate®.
